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SConclusions: Whilst GpIIb/IIIa inhibitor use was associated with a signiﬁcant
protective effect on Kaplan–Meier survival analysis, this disappeared when the
signiﬁcant baseline disparities seen in these patients were accounted for.
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Background: Drug-eluting stents (DES) have been related to a certain risk of late
thrombosis. The recommended duration of dual antiplatelet therapy (DAPT) with DES
is 12 months. DAPT is not free from complications and is expensive. Trials with
limited size suggest that a 6 month DAPT period could be enough with new gener-
ation DES. There are no prospective clinical registries assessing the safety of such
approach.
Methods: All consecutive patients treated with a new generation DES (Xience V,
Xience Prime, Endeavor Resolute, Promus Element, Biomatrix, Nobori, Osiro) were
prospectively included in 20 different centers. Patients had to fulﬁll one of the
following inclusion criteria in order to have 6 month DAPT period prescribed: silent
ischemia, stable angina, low risk non-ST segment elevation myocardial infarction or
acute coronary syndrome where 12 months DAPT was discarded due to high bleeding
risk. Taking advantage of the ESTROFA-2 database (4,768 patients treated with new
generation DES, 4355 of them with 12 months DAPT) we will perform a propensity
score matching of the six months DAPT from the ESTROFA-DAPT registry with the
12 months DAPT from the ESTROFA-2 registry.
Results: A total of 800 patients have been included so far in 20 centers. The baseline
characteristics of the matched groups and the 1 year follow up results of the ﬁrst 500
patients would be presented at the meeting sessions.
Conclusions: The ESTROFA-DAPT registry will provide data regarding safety of a 6
month DAPT period after new generation DES implantation.
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Background: Prolonged dual anti-platelet therapy (DAPT) is recommended after an
acute coronary syndrome (ACS) to reduce ischemic events, but is associated with
increased rates of major and minor bleeding. The incidence of even lesser degrees of
'nuisance' bleeding on DAPT and its impact on quality of life (QOL) are largely
unknown.
Methods: We studied 9290 ACS patients from the TRANSLATE ACS study who
were treated with PCI and discharged alive between April 2010 to Sept 2012.
Bleeding post-hospital discharge was deﬁned via the BARC bleeding deﬁnitions. Our
primary outcome was the 6 month EQ-5D index score, based on the U.S. population
preference weights. The EQ5D visual analog scale (VAS) at 6 months was
a secondary outcome. To determine the association between nuisance bleeding and 6-
month QOL, we ﬁt a mixed-effects linear regression model for 6 month EQ5D index
adjusting for baseline EQ5D index, with site as random effect (hierarchical model) and
other confounders of the relationship between bleeding and health status. We ﬁt
a similar model for EQ5D visual analog scale (VAS).
Results: Of the 9,290 patients with ACS (mean age 61, 73% males, 89% Whites),
4134 (44.5%) underwent immediate PCI for STEMI, and 4308 (46.4%) underwent
PCI for non-STEMI. A total of 849 (9.1%) patients experienced BARC I type
nuisance bleeding. Those who experienced BARC I bleeding had lower scores on all 5
EQ5D domains (mobility, self-care, usual activities, pain and anxiety) and had a lower
5 point EQ5D VAS score. After adjustment for confounders, nuisance bleeding by 6
month was independently associated with a decrement in QOL at 6 month (-2.04JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrpoints on EQ5D VAS; 95% CI -0.93 to -3.15, P<0.001). Based on the EQ5D index
score, the utility decrement associated with nuisance bleeding was 0.026, 95% CI
0.015 to 0.037, P-value <0.001.
Conclusions: In TRANSLATE-ACS, we found that BARC Type I (nuisance)
bleeding occurred in 1 of 10 patients after an ACS event and was associated with
worse 6-month quality of life and utility. These ﬁndings suggest that even nuisance
bleeds are relevant to patients and deserve greater attention in clinical recommenda-
tions for treatment and future clinical trials of prolonged DAPT therapies.
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Background: Platelet surface P-selectin and activated GPIIb-IIIa are markers of
platelet activation, degranulation and aggregation. In the TRITON trial prasugrel
(Pras) 10 mg reduced ischemic events vs. clopidogrel (Clop) 75 mg but increased
bleeding, notably in very elderly (VE) patients. Pras 5 mg is a treatment option in VE
patients but data on its effect on GPIIb-IIIa and P-selectin expression is lacking. We
performed a blinded, three-period cross-over study in stable CAD patients 75 y (VE)
or 45-65 y (NE) examining expression of these biomarkers following Pras (5 or 10
mg) and Clop 75 mg.
Methods: After a run-in on low dose aspirin, VE subjects (n¼23, 78  5 y) and NE
subjects (n¼22, 55  5 y) were randomized to Pras (5 or 10 mg) or Clop 75 mg during
three 12-day periods. ADP (20 mM)-stimulated platelet P-selectin and GPIIb-IIIa
(PAC-1) were measured by ﬂow-cytometry at baseline and at the end of each12-day
dosing period.
Results: PAC-1 and P-selectin (data not shown) expression after stimulation with 20
mM ADP did not differ between VE and NE at baseline or after any treatment period
(Figure). PAC-1 expression was signiﬁcantly reduced by pras 5 mg in both VE
(p<0.01) and NE (p<0.05). In the VE the 5 mg dose had similar effect as pras 10 mg.
Clop 75 mg did not signiﬁcantly reduce PAC-1 in VE. P-selectin expression showed
a similar proﬁle (data not shown).Conclusions: As assessed by GPIIb-IIIa and P-selectin in stable CAD patients, Pras 5
mg signiﬁcantly reduced ADP-induced platelet activation in the VE.
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Background: Increasingly cardiologists need to place coronary artery disease patients
implanted with drug-eluting stents on dual antiplatelet therapy (DAPT) regimens of
durations shorter than the 6-12 months recommended in current guidelines. Unfor-
tunately, no sufﬁcient clinical data are available to support such shorter DAPT
durations.
Methods: This prospective, nonrandomized, multicenter, controlled study of the
Endeavor zotarolimus-eluting stent (E-ZES) in real world Japanese patients consists of
two arms: patients who were enrolled at 106 medical institutions to receive DAPT for
3 months and then followed for 1year, and a 12-month DAPT arm consisting of
patients consecutively extracted from patients enrolled in the Endeavor Japan post-
marketing surveillance. The analysis was done on an intent to treat basis. Theacts/POSTER/Antiplatelets and Antithrombins B45







Sprespeciﬁed primary endpoint is the comparison of "NACCE" or net adverse cardiac
and cerebrovascular events (death, myocardial infarction, cerebrovascular accident,
and major bleeding) at 12 months after implantation. After performing propensity
scoring to adjust for differences in baseline characteristics, the noninferiority of the 3-
month DAPT arm to the 12-month DAPT arm will be assessed with respect to the
incidence of NACCE.
Results: There were 1,205 patients enrolled in the 3-month DAPT arm and 1,345
patients included on the 12-month DAPT arm. Baseline characteristics of both groups
were: men, 75.4% and 74.3%; mean age, 68.7 and 67.6 years; diabetes, 32.6% and
35.0%; acute coronary syndrome, 40.7% and 36.3%; number of lesions, 1,453 and
1,738; target vessel lesions,LMCA (0.3% and 0%), LAD (51.3% and 43.4%), LCX
(18.4% and 18.4%), and RCA (30.0% and 38.2%); de novo lesions, 99.3% and
97.5%; reference vessel diameter, 2.71 mm and 2.58 mm; pre-minimum lumen
diameter, 0.81 mm and 0.75 mm; pre-% diameter stenosis, 70.0% and 71.0%; lesion
length, 15.7 mm and 16.8 mm; and total stent length, 21.4 mm and 24.4 mm.
Conclusions: Baseline characteristics of both arms were similar. The present study
will provide insight into the optimal duration of DAPT after E-ZES implantation. Per-
protocol analysis results will be presented at TCT in 2013.
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Background: Cilostazol may have a positive chronotropic or pro-arrhythmic effect,
despite its beneﬁcial effects on vasodilation and antiplatelet aggregation. However, it
is unknown whether adjunctive cilostazol can contribute to tachycardia or arrhythmias
after drug-eluting stents (DES) implantation. The aim of this study was to determine
the impacts of adjunctive cilostazol on 24-hour heart rate and arrhythmias in patients
undergoing DES implantation.
Methods: This randomized, multicenter, prospective trial compared triple antiplatelet
therapy (aspirin, clopidogrel, and cilostazol, TAT, n ¼ 113) and dual antiplatelet
therapy (aspirin and clopidogrel, DAT, n ¼ 114) at baseline and 6-month in patients
receiving DES. The primary end points were 24-hour heart rate (24h-HR), 24h-HR
70 bpm, and 24h-HR increase 5 bpm at 6-month follow-up using 24-hour Holter
electrocardiographic monitoring. Secondary end points were counts or presences of
premature ventricular complex (PVC), nonsustained ventricular tachycardia, sustained
ventricular tachycardia, premature atrial complex, and supraventricular tachycardia at
6-month.
Results: The two groups had similar baseline characteristics. At 6-month follow-up,
the 24h-HR (75.4  11.7 bpm vs. 69.3  10.0, p < 0.001), presence of 24h-HR 70
bpm (71.4% vs. 47.1%, p < 0.001), and presence of 24h-HR increase 5 bpm (44.8%
vs. 24.5%, p ¼ 0.002) were signiﬁcantly higher in the TAT versus DAT group.
Multivariate analysis showed that the use of cilostazol (OR: 3.10, 95% CI: 1.08 to
8.89) and baseline 24-HR < 70 bpm (OR: 4.60, 95% CI: 1.16-13.14) were strong
predictors of 24h-HR increase 5 bpm at follow-up. In addition, 24h total counts of
PVCs (472  1497 beats vs. 86  209 beats, p ¼ 0.016) was signiﬁcantly higher in
the TAT versus DAT group among the secondary end points.
Conclusions: Cilostazol in addition to DAT appears to result in an increase in 24h-HR
and total counts of PVCs after DES implantation. Some caution should be exercised
for the use of cilostazol in patients with tachycardia or a large number of PVCs, when
planning DES implantation.
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Background: The present study aims to evaluate the impact of hemoglobin and
hematocrit (H&H) on different assay methods used to test on-treatment platelet
reactivity to clopidogrel.
Methods: Platelet reactivity was tested in 466 consecutive patients with VerifyNow
(VN) P2Y12, vasodilator-stimulated phosphoprotein phosphorylation (VASP), and
light transmission aggregometry (LTA) with adenosine diphosphate (ADP) 5- and 20-B46 JACC Vol 62/18/Suppl B j October 27–NovemmM assay 6 to 24 hours after PCI. Low hemoglobin was deﬁned as level <12 for
women and <13 for men. Patients were stratiﬁed into low and normal hemoglobin
groups.
Results: Using VN-P2Y12 assay, patients with low hemoglobin had higher, mean
PRU (211119 vs.15894, p<0.001) and higher BASE values (34154 vs. 28858,
p<0.001) compared to patients with normal hemoglobin. The reported mean percent
inhibition (4037 vs. 4631, p¼0.16) was similar between groups. No differences
were noted in mean platelet reactivity between the two groups by LTA ADP 5mM
(3818 vs. 3514, p¼0.12), ADP 20mM (4720 vs. 4417, p¼0.19) and VASP
(4127 vs.3826, p¼0.27). In a multivariate logistic regression model, baseline
hematocrit was an independent correlate for PRU208 (OR 0.91, 95% CI 0.86-0.96)
but has no impact on HTPR by LTA ADP 5 mM 46 (OR 1.0, 95% CI 0.95-1.05),
LTA ADP 20 mM 59 [OR 1.01, 95% CI 0.96-1.06) or VASP PRI50% [OR 1.0,
95% CI 0.95-1.05).Conclusions: The results show that the on-treatment platelet reactivity to clopidogrel
measured by VerifyNow P2Y12 PRU is signiﬁcantly inﬂuenced by patient's baseline
H&H, while the platelet reactivity measured by LTA and VASP does not seem to be
impacted.
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Background: It has been well known that the inhibition of platelet aggregation (IPA)
by anti-platelet agents was important to reduce the thrombo-embolic events in patients
with ST segment elevation myocardial infarction (STEMI). However, the peri-
procedural IPA by anti-platelet agents was not well known.
Methods: We compared the peri-procedural IPA between prasugrel and adjunctive
cilostazol to dual anti-platelet therapy (Triple anti-platelet therapy; TAP) in patients
with STEMI undergoing primary percutaneous coronary intervention (PCI). We
prospectively randomized 70 consecutive clopidogrel-naive patients with STEMI
planned PCI to either prasugrel [loading dose (LD) 60 mg; 37 patients] or TAP (LD
aspirin 300 mg, clopidogel 600 mg, and cilostazol 200 mg; 33 patients). Primary end
points of the study were the platelet reactivity unit (PRU) or % inhibition by the
VerifyNow P2Y12 assay at pre-PCI and pre-discharge.
Results: The drug loading to pre-PCI time was similar between prasugrel and TAP
groups (25.4  10.42 minutes vs. 25.5  10.56 minutes, p ¼ 0.957). PRU at pre-PCI
was signiﬁcantly lower in prasugrel than in TAP (269.1  71.69 vs. 306.5  48.67,
p ¼ 0.012). The lower PRU and greater % inhibition also observed in prasugrel than in
TAP at pre-discharge (108.2  60.51 vs. 238.1  73.40; 63.6  18.51% vs. 16.8 
17.91%, p <0.001 respectively). No differences in in-hospital bleeding complications
between two groups were observed.
Conclusions: Our study demonstrates that prasugrel could produce a signiﬁcantly
greater peri-procedural as well as in-hospital IPA compared with TAP in patients with
STEMI undergoing primary PCI.ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
